Anavex Life Sciences (AVXL) stock
Follow AVXL's trial news. Members get an alert when Anavex Life Sciences files news, and see its trials, share raises, and its CEO's filings.
What's next for AVXL, and how long its cash lasts
From Anavex Life Sciences’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
About 16 quarters
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.
Why AVXL scores -2
PoorTrending down, 3 of 13 possible checks firingWhat the Quality Score means
- +3Momentum traits 3 firing right now, of 13 possible, one point each
- −3Long-term trend below a falling 200-day, down over one year, down over two years
- Size subtracts
- Volatility subtracts
- Cash flow subtracts
- News adds
What's next
Expected to report Tue Nov 24, before the open
After its last 3 reports it closed +11.0% on average, higher 3 of 3 times.
What would turn AVXL's score around: 7 things, for members
Here is what members see.
Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.
AVXL has 3 of a possible 13 checks firing
14 checks. Two are opposites (heavy volume and quiet volume), so at most 13 are on at once. One per group is shown here.
How AVXL ranks in Biotech
AVXL is #171 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.
RGEN9/1321
ABCL10/1320
XERS9/1319
HALOOpen for its score
ONCOpen for its score
AVXL3/13-2
When does AVXL report, and what happens after?
Expected to report Tue Nov 24, before the open (in 57 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 25, 2026Before open | Before open | +8.4% | +14.5% | -10.0% |
| Feb 9, 2026Before open | Before open | +2.4% | +6.1% | -4.2% |
| Nov 25, 2025Before open | Before open | +6.8% | +12.3% | +19.2% |
About Anavex Life Sciences
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of AVXL's score, with the points and the reason
- All 14 checks on AVXL and on all 2,951 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on AVXL
Straight answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.
What does it cost?
Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.